Over the past 12 months, 9 insiders at Aktis Oncology, Inc. filed 17 open-market SEC Form 4 transactions on AKTS: 9 purchases worth $114.3M and 8 sales worth $2.9M. Insiders have been mixed over this period. The most recent filing was on Jul 20, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 20, 26 | Ken HerrmannDirector | SELL | 3.5K | $24.56 | $86K |
| Jul 8, 26 | Akos CzibereChief Medical Officer | SELL | 30.8K | $28.71 | $862K |
| Jul 8, 26 | Shulamit Ron-biggerChief Operating Officer | SELL | 30.0K | $28.75 | $838K |
| Jan 12, 26 | Todd FoleyDirector,TenPercentOwner | BUY | 232.9K | $18.00 | $4.2M |
| Jan 12, 26 | Ansbert GadickeTenPercentOwner | BUY | 1.11M | $18.00 | $20.0M |
| Jan 12, 26 | Helen Susan KimDirector,TenPercentOwner | BUY | 812.5K | $18.00 | $14.6M |
| Jan 12, 26 | Mpm Oncology Innovations Fund LpTenPercentOwner | BUY | 1.11M | $18.00 | $20.0M |
| Jan 12, 26 | Oleg NodelmanDirector | BUY | 2.08M | $18.00 | $37.4M |
| Jan 12, 26 | Vida Ventures Ii-a, LlcTenPercentOwner | BUY | 812.5K | $18.00 | $14.6M |
| Jan 29, 24 | David AicheleEVP of Business Development | BUY | 80.0K | $0.50 | $40K |
| Jan 29, 24 | Kenneth BollerCFO | BUY | 60.0K | $0.50 | $30K |
| Jan 29, 24 | Arthur GeissDirector | BUY | 50.0K | $0.50 | $25K |
| Jan 29, 24 | Jeffrey B. ShealyChief Executive Officer | BUY | 1.31M | $0.50 | $655K |
| Dec 18, 23 | David AicheleEVP of Business Development | SELL | 1.5K | $0.72 | $1K |
| Dec 18, 23 | Kenneth BollerCFO | SELL | 1.2K | $0.72 | $864 |
| Nov 21, 23 | David AicheleEVP of Business Development | SELL | 2.6K | $0.59 | $2K |
| Nov 21, 23 | Kenneth BollerCFO | SELL | 1.7K | $0.59 | $1K |
| Sep 11, 23 | David AicheleEVP of Business Development | SELL | 5.3K | $1.09 | $6K |
| Sep 11, 23 | Kenneth BollerCFO | SELL | 3.9K | $1.10 | $4K |
| Aug 18, 23 | Steven DenbaarsDirector | SELL | 7.0K | $1.83 | $13K |
| Feb 10, 23 | Kenneth BollerCFO | SELL | 800 | $4.37 | $3K |
| Dec 20, 22 | Jeffrey B. ShealyChief Executive Officer | SELL | 2.3K | $2.84 | $7K |
| Dec 19, 22 | David AicheleEVP of Business Development | SELL | 1.5K | $3.14 | $5K |
| Dec 19, 22 | Kenneth BollerCFO | SELL | 1.2K | $2.92 | $4K |
| Dec 6, 22 | Steven DenbaarsDirector | SELL | 7.0K | $3.57 | $25K |
| Nov 28, 22 | Jeffrey B. ShealyChief Executive Officer | SELL | 1.9K | $3.54 | $7K |
| Nov 23, 22 | David AicheleEVP of Business Development | SELL | 1.9K | $3.52 | $7K |
| Nov 23, 22 | Kenneth BollerCFO | SELL | 1.2K | $3.52 | $4K |
| Sep 9, 22 | Jeffrey B. ShealyChief Executive Officer | SELL | 3.9K | $4.30 | $17K |
| Sep 6, 22 | Steven DenbaarsDirector | SELL | 7.0K | $3.90 | $27K |
| Aug 29, 22 | David AicheleEVP of Business Development | SELL | 3.7K | $4.53 | $17K |
| Aug 29, 22 | Kenneth BollerCFO | SELL | 2.4K | $4.53 | $11K |
| Aug 29, 22 | Jeffrey B. ShealyChief Executive Officer | SELL | 3.9K | $4.54 | $18K |
| Aug 22, 22 | David AicheleEVP of Business Development | SELL | 1.5K | $4.62 | $7K |
| Aug 22, 22 | Kenneth BollerCFO | SELL | 1.5K | $4.62 | $7K |
| Jul 18, 22 | David AicheleEVP of Business Development | SELL | 2.3K | $3.68 | $9K |
| Jun 6, 22 | Steven DenbaarsDirector | SELL | 7.0K | $4.48 | $31K |
| Apr 8, 22 | David AicheleEVP of Business Development | SELL | 5.0K | $5.93 | $30K |
| Feb 7, 22 | James Michael McGuireDirector | BUY | 17.8K | $5.62 | $100K |
| Jan 11, 22 | Steven DenbaarsDirector | SELL | 7.0K | $5.91 | $41K |
| Dec 20, 21 | David AicheleEVP of Business Development | SELL | 1.5K | $6.64 | $10K |
| Dec 20, 21 | Kenneth BollerInterim CFO | SELL | 2.1K | $6.69 | $14K |
| Dec 17, 21 | Jeffrey B. ShealyChief Executive Officer | SELL | 13.9K | $7.01 | $98K |
| Nov 23, 21 | David AicheleEVP of Business Development | SELL | 1.9K | $6.77 | $13K |
| Nov 23, 21 | Kenneth BollerInterim CFO | SELL | 900 | $6.97 | $6K |
| Nov 9, 21 | Suzanne B RudyDirector | SELL | 12.7K | $8.11 | $103K |
| Oct 29, 21 | Arthur GeissDirector | SELL | 10.0K | $7.47 | $75K |
| Oct 11, 21 | Steven DenbaarsDirector | SELL | 7.0K | $8.08 | $57K |
| Sep 27, 21 | David AicheleEVP of Business Development | SELL | 1.4K | $10.60 | $15K |
| Aug 30, 21 | David AicheleEVP of Business Development | SELL | 1.9K | $9.04 | $17K |
Over the past 12 months, insiders at Aktis Oncology, Inc. filed 9 open-market purchases worth $114.3M and 8 sales worth $2.9M on AKTS, which makes them mixed over the period. The most recent Form 4 was filed on Jul 20, 26.
The largest recent open-market AKTS insider purchase in our data was $37.4M by Oleg Nodelman, Director, filed on Jan 12, 26.
9 different insiders at Aktis Oncology, Inc. filed open-market SEC Form 4 transactions on AKTS over the last 12 months.
InsiderTape plots every AKTS insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Aktis Oncology, Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →